A Phase 2 interventional study of NMDAE and Placebo Cap in Major Depressive Disorder, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 51st largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2022, is one of 8 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 53rd registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Argentina and 4 more countries
Ages 18–74
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Brazil and 4 more countries
Ages 12–17
National Science and Technology Council, Taiwan · Sites in Taiwan
Ages 50–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 19 · Phase 4 10
First in 2005; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 128 across the 64 interventional studies, 160 across the 5 observational. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
China Medical University Hospital is the lead sponsor of 480 studies on the registry; 116 are open to participants now.
China Medical University Hospital has 7 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder, Major with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04637620China Medical University HospitalNMDA Modulation in Major Depressive Disorder | 2026-11 |
| NCT05136755China Medical University HospitalNMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder | 2026-11 |
| NCT06821646National Taiwan University HospitalInvestigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography | 2026-12-31 |
| NCT07500714National Science and Technology Council, TaiwanIntegrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Major depressive disorder (MDD) is a multi-factorial disorder. Most of the current antidepressants are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. Many patients respond poorly to antidepressants and suffer from side effects. NMDA hypofunction has been implicated in the pathophysiology of depression. MDD is often associated with cognitive deficits which are not necessarily recovered by current antidepressants. The NMDA receptor regulates synaptic plasticity, memory, and cognition. Therefore, this study aims to examine the efficacy and safety as well as cognitive function improvement of NMDAE in the treatment of antidepressant nonresponders with MDD. The investigators will enroll a total of 50 antidepressant nonresponders with MDD. All patients, continuing their originally ongoing treatment throughout the study period, will be randomly assigned into either of two treatment groups: NMDAE or placebo. We will biweekly measure clinical performances using 17-item Hamilton Rating Scale for Depression, Global Assessment of Function, Perceived Stress Scale, Visual Analogue Scale for pain, Clinical Global Impression, and side effects. Quality of life and cognitive functions will be assessed at baseline and at endpoint of treatment.
The efficacies of NMDAE and placebo will be compared. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An NMDA enhancer
Drug: NMDAE
Placebo
Drug: Placebo Cap
Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
Use of placebo as a comparator
Change in Hamilton Rating Scale for Depression
Assessment of depressive symptoms Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.
Time frame: week 0, 2, 4, 6, 8
Change in Global Assessment of Functioning
Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome.
Time frame: Week 0, 2, 4, 6, 8
Change Change in Perceived Stress Scalein Perceived Stress Scale
Assessment of stress and anxiety symptoms Minimum value: 0, maximum value:56, the higher scores mean a worse outcome.
Time frame: week 0, 2, 4, 6, 8
Visual Analogue Scale for pain
Assessment of pain Minimum value: 0, maximum value:10, the higher scores mean a worse outcome.
Time frame: week 0, 2, 4, 6, 8
Clinical Global Impression
Time frame: week 0, 2, 4, 6, 8
Quality of life (SF-36)
Time frame: week 0, 8
Visual Continuous Performance Test
Assessment of sustained attention
Time frame: week 0, 8
Wisconsin Card Sorting Test
Assessment of abstract and shift set
Time frame: week 0, 8
Logical Memory Test of the Wechsler Memory Scale
Assessment of episodic memory
Time frame: week 0, 8
Digit Span
Assessment of verbal working memory
Time frame: week 0, 8
Spatial Span
Assessment of nonverbal working memory
Time frame: week 0, 8
Category Fluency
Assessment of speed of processing
Time frame: week 0, 8
Trail Marking A
Assessment of speed of processing
Time frame: week 0, 8
WAIS-III Digit Symbol-Coding
Assessment of speed of processing
Time frame: week 0, 8
Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0
Assessment of social cognition
Time frame: week 0, 8
Started Jan 2022 (actual). Primary completion is estimated for Nov 2026, 58 months after the start.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 58 months is above that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital →